tert-butyl 4-((2-(tert-butoxy)-2-oxoethoxy)methyl)piperidine-1-carboxylate | 930294-35-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl 4-((2-(tert-butoxy)-2-oxoethoxy)methyl)piperidine-1-carboxylate
• 英文别名: [(1-tert-butoxycarbonylpiperidin-4-yl)methoxy]acetic acid tert-butyl ester；tert-butyl 4-[[2-[(2-methylpropan-2-yl)oxy]-2-oxoethoxy]methyl]piperidine-1-carboxylate
• CAS: 930294-35-2
• 化学式: C₁₇H₃₁NO₅
• 分子量: 329.437
• InChiKey: YLWMCUBBYRPUTG-UHFFFAOYSA-N

物化性质

• 沸点：
  410.4±15.0 °C(Predicted)
• 密度：
  1.046±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  23
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  65.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-((2-(tert-butoxy)-2-oxoethoxy)methyl)piperidine-1-carboxylate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 5.0h， 生成 2-(piperidin-4-ylmethoxy)acetic acid
  参考文献：
  名称：

  [EN] NOVEL NON-SYSTEMIC TGR5 AGONISTS
  [FR] NOUVEAUX AGONISTES DE TGR5 NON SYSTÉMIQUES

  摘要：

  公开号：

  WO2018005794A3
• 作为产物：
  描述：

  溴乙酸叔丁酯 、 N-Boc-4-哌啶甲醇 在 sodium hydroxide 、 四丁基溴化铵 作用下， 以 水 为溶剂， 反应 24.5h， 以67%的产率得到tert-butyl 4-((2-(tert-butoxy)-2-oxoethoxy)methyl)piperidine-1-carboxylate
  参考文献：
  名称：

  EP1939201

  摘要：

  公开号：

文献信息

• NOVEL ADENINE COMPOUND
  申请人：Isobe Yoshiaki

  公开号：US20090105212A1

  公开（公告）日：2009-04-23

  A novel adenine compound represented by the formula (1): wherein A represents an (un)substituted aromatic carbocycle or (un)substituted aromatic heterocycle; L 1 , L 2 , and L 3 each independently represents linear or branched alkylene, etc.; R 1 represents (un)substituted alkyl, (un)substituted aryl, etc.; R 2 represents hydrogen or (un) substituted alkyl; R 3 represents (un)substituted alkyl, etc., provided that R 3 may be bonded to L 2 or L 3 to form a nitrogenous saturated heterocycle; and X represents oxygen, etc.; or a pharmaceutically acceptable salt of the compound. The compound and salt are useful as a medicine.

  一种新型腺嘌呤类化合物，其化学式为（1）：其中A代表（未）取代芳香族碳环或（未）取代芳香族杂环；L1，L2和L3分别独立地代表线性或支链烷基等；R1代表（未）取代烷基，（未）取代芳基等；R2代表氢或（未）取代烷基；R3代表（未）取代烷基等，但R3可与L2或L3结合形成含氮饱和杂环；X代表氧等；或该化合物的药学上可接受的盐。该化合物和盐作为药物有用。
• Non-systemic TGR5 agonists
  申请人：Venenum Biodesign, LLC

  公开号：US10654834B2

  公开（公告）日：2020-05-19

  The present invention relates to tricyclic compounds of formula (I) and formula (II), or a pharmaceutically acceptable salt thereof. The present tricyclic compounds are useful non-systemic TGR5 agonists that can be used to treat diabetic diseases in human. The present invention provides a pharmaceutical composition containing tricyclic compounds of formula (I) and formula (II) and a method of making as well as a method of using same in treating patients inflicted with metabolic disorders by administering same. The compounds of the present invention may be used in combination with additional anti-diabetic drugs.

  本发明涉及式（I）和式（II）的三环化合物或其药学上可接受的盐。本发明的三环化合物是有用的非系统性 TGR5 激动剂，可用于治疗人类糖尿病疾病。本发明提供了一种含有式（I）和式（II）三环化合物的药物组合物及其制造方法，以及一种通过给药治疗代谢紊乱患者的方法。本发明的化合物可与其他抗糖尿病药物联合使用。
• EP1939201
  申请人：——

  公开号：——

  公开（公告）日：——
• NOVEL NON-SYSTEMIC TGR5 AGONISTS
  申请人：Venenum Biodesign, LLC

  公开号：US20190330191A1

  公开（公告）日：2019-10-31

  The present invention relates to tricyclic compounds of formula (I) and formula (II), or a pharmaceutically acceptable salt thereof. The present tricyclic compounds are useful non-systemic TGR5 agonists that can be used to treat diabetic diseases in human. The present invention provides a pharmaceutical composition containing tricyclic compounds of formula (I) and formula (II) and a method of making as well as a method of using same in treating patients inflicted with metabolic disorders by administering same. The compounds of the present invention may be used in combination with additional anti-diabetic drugs.
• [EN] NOVEL NON-SYSTEMIC TGR5 AGONISTS<br/>[FR] NOUVEAUX AGONISTES DE TGR5 NON SYSTÉMIQUES
  申请人：VENENUM BIODESIGN LLC

  公开号：WO2018005794A3

  公开（公告）日：2018-02-08